Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
MEDP Stock Chart & Stats
$590.09
$7.21(2.08%)
At close: 4:00 PM EST
$590.09
$7.21(2.08%)
Day’s Range― - ―
52-Week Range$250.05 - $625.00
Previous CloseN/A
Volume64.09K
Average Volume (3M)319.15K
Market Cap
$16.62B
Enterprise Value$14.68B
Total Cash (Recent Filing)$285.35M
Total Debt (Recent Filing)$143.97M
Price to Earnings (P/E)41.3
Beta1.18
Next Earnings
Feb 16, 2026EPS Estimate
4.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.86
Shares Outstanding28,168,222
10 Day Avg. Volume248,471
30 Day Avg. Volume319,153
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)12.46
Price to Sales (P/S)4.88
P/FCF Ratio17.97
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue6.22
Enterprise Value/Gross Profit20.00
Enterprise Value/Ebitda28.18
Forecast
1Y Price Target
$524.89Price Target Upside-11.05% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)14.81
Revenue Forecast (FY)$2.51B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceShares are currently up 9% on the back of another staggering beat-and-raise quarter from Medpace.
Market PositionMEDP's unique position in the faster-growing SMid-biotech space deserves a premium valuation.
Revenue GrowthRevenue from metabolic trials increased over 80% year-over-year and nearly 33% sequentially.
Bears Say
Margin PressureAn upcoming re-acceleration in hiring will likely create some near/medium-term pressure on margins.
Peer ComparisonThe stock is now trading at 41.0x our current 2026 EPS estimate, significantly above its peer group average of 15.5x.
Valuation ConcernsMedpace Holdings' current trading valuation is at all-time high levels, which may not align with the expected fundamental performance.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $250.05 and its highest was $625.00 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $16.62B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Feb 16, 2026 which is in 91 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Oct 22, 2025. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.535 by $0.325.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Overvalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 4.19.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 28,168,222 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $3.86 in its last earnings report, beating expectations of $3.535. Following the earnings report the stock price went up 9.121%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MEDP
Medpace Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$524.89 (-11.05% Downside)
$524.89 (-11.05% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 44.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $68.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.23%
12-Months-Change
Fundamentals
Return on Equity
73.70%
Trailing 12-Months
Asset Growth
-15.88%
Trailing 12-Months
Company Description
Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Company Deck
MEDP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and business growth, with significant net new business awards and a record net book-to-bill ratio. Despite these positive aspects, there were challenges related to a higher effective tax rate, lower interest income, and cancellations. Overall, the call demonstrates a strong performance with some areas for improvement.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$524.89
▼(-11.05% Downside)
Technical Analysis
Ownership Overview
20.49% Insiders
22.88% Mutual Funds
28.29% Other Institutional Investors
6.60% Public Companies and
Individual Investors